Abstract
Anti-VEGF pharmacotheraphy has recently become popular for the treatment of retinal vascular diseases due to the stabilization or even improvement of vision with these agents. Herein, we report a rare corneal complication of anti-VEGF treatment with pegaptanib (Macugen; OSI Inc. and Pfizer Inc., New York, NY, USA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
